These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1673498)

  • 1. Enough evidence to operate?
    Lancet; 1991 May; 337(8749):1066-7. PubMed ID: 1673498
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast cancer mucin antigen (BCM) determination by IMX: a preliminary study of epidemiological distribution of the serum levels in gynecological diseases.
    Torre GC; Barbetti V; Lanfranco E; Robutti M; Foglia M; Corongiu F; Vigliercio GP
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):59-62. PubMed ID: 2092151
    [No Abstract]   [Full Text] [Related]  

  • 3. Is a high CA 125 antigen level in the absence of anatomic evidence for tumor an indication for laparotomy?
    Gocze PM; Freeman DA
    Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 1):1896-7. PubMed ID: 8317541
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical use of gynaecologic tumour markers.
    Halila H; Alfthan H; Stenman UH
    Ann Chir Gynaecol; 1989; 78(1):65-70. PubMed ID: 2547331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialyl Lewis-Xi antigen in patients with gynecologic tumors.
    Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saito J; Tanizawa O
    Obstet Gynecol; 1989 Jan; 73(1):79-83. PubMed ID: 2909045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of the tumor markers CA 125, Ca 19-9, CA 15-3 and CEA in endometriosis].
    Cirkel U; Ochs H; Latussek B; Schneider HP
    Geburtshilfe Frauenheilkd; 1991 Aug; 51(8):626-31. PubMed ID: 1936874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical usefulness of CA M26 and CA M29 in breast carcinoma].
    Quaranta M; Micelli G; Coviello M; Donadeo A; Lozupone A; Schittulli F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):35-8. PubMed ID: 2092146
    [No Abstract]   [Full Text] [Related]  

  • 8. Breast cancer and tumor markers.
    Castellaro E; Francioni S; Pastore M
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):43-7. PubMed ID: 2092148
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
    Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
    [No Abstract]   [Full Text] [Related]  

  • 10. [Determination of MCA, CA 15.3, CA M26, in carcinoma of the breast].
    Bumma C; Bramardi AM; Lauria G; Arese P; Marchetti G
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):29-32. PubMed ID: 2092137
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumour markers in gynaecologic oncology.
    Onsrud M
    Scand J Clin Lab Invest Suppl; 1991; 206():60-70. PubMed ID: 1719611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
    Seifert M; Wierrani F; Kubista E; Spona J
    Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of MCA and CA 15-3 in tissue and in serum of patients with breast carcinoma: preliminary results.
    Reale G; Giovagnoli MR; Vecchione A; Cosentino L; Benci F; Manna A; Marchei G; Vittori I; Frati L
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):53. PubMed ID: 2092150
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
    Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
    Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
    Fritsche E; Benz J
    Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experiences with the cancer marker CA 125 in gynecologic diseases].
    Pilgrim G; von Broen B; Johannsmeyer KD
    Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian rhythms of tumor markers in breast cancer patients.
    Touitou Y; Bailleul F; Lévi F; Bogdan A; Touitou C; Metzger G; Mechkouri M
    Prog Clin Biol Res; 1990; 341A():59-66. PubMed ID: 2217278
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAM 26 and CAM 29: methodological evaluations and first clinical employment in breast cancer.
    Priolo G; Pecchio F; Rapellino M; Aimo G; Spertino F; Pepe C
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):21-3. PubMed ID: 2092121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.